G. L. Utermann, C. Scriver, A. Beaudet, W. Sly, and D. Valle, The Metabolic and Molecular Bases of Inherited Disease, pp.2753-2787, 2001.

P. Kamstrup, A. Tybjaerg-hansen, R. Steffensen, and B. Nordestgaard, Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction, JAMA, vol.301, issue.22, pp.2331-2339, 2009.
DOI : 10.1001/jama.2009.801

S. Erqou, S. Kaptoge, P. Perry, A. Di, A. Thompson et al., Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, vol.302, pp.412-423, 2009.

R. Clarke, J. Peden, J. Hopewell, T. Kyriakou, A. Goel et al., Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease, New England Journal of Medicine, vol.361, issue.26, pp.2518-2528, 2009.
DOI : 10.1056/NEJMoa0902604

K. Matthews, M. Sowers, C. Derby, E. Stein, H. Miracle-mcmahill et al., Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN), American Heart Journal, vol.149, issue.6
DOI : 10.1016/j.ahj.2004.08.027

B. Cantin, F. Gagnon, S. Moorjani, J. Despres, B. Lamarche et al., Is Lipoprotein(a) an Independent Risk Factor for Ischemic Heart Disease in Men? The Quebec Cardiovascular Study, Journal of the American College of Cardiology, vol.31, issue.3, pp.519-525, 1998.
DOI : 10.1016/S0735-1097(97)00528-7

G. Luc, J. Bard, D. Arveiler, J. Ferrieres, A. Evans et al., Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study, Atherosclerosis, vol.163, issue.2, pp.377-384, 2002.
DOI : 10.1016/S0021-9150(02)00026-6

D. Suk, N. Rifai, J. Buring, and P. Ridker, Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women, JAMA, vol.296, pp.1363-1370, 2006.

J. Danesh, R. Collins, and R. Peto, Lipoprotein(a) and Coronary Heart Disease : Meta-Analysis of Prospective Studies, Circulation, vol.102, issue.10, pp.1082-1085, 2000.
DOI : 10.1161/01.CIR.102.10.1082

A. Bennet, A. Di, S. Erqou, G. Eiriksdottir, G. Sigurdsson et al., Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease<subtitle>Large-Scale Prospective Data</subtitle>, Archives of Internal Medicine, vol.168, issue.6, pp.598-608, 2008.
DOI : 10.1001/archinte.168.6.598

P. Kamstrup, M. Benn, A. Tybjaerg-hansen, and B. Nordestgaard, Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study, Circulation, vol.117, issue.2, pp.176-184, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.715698

G. Smith and S. Ebrahim, Mendelian randomization: prospects, potentials, and limitations, International Journal of Epidemiology, vol.33, issue.1, pp.30-42, 2004.
DOI : 10.1093/ije/dyh132

URL : http://ije.oxfordjournals.org/cgi/content/short/33/1/30

J. Goldstein, H. Hobbs, M. Brown, C. Scriver, A. Beaudet et al., Familial hypercholesterolemia The Metabolic and Molecular Bases of Inherited Disease, pp.2863-2913, 2001.

A. Tybjaerg-hansen, R. Steffensen, H. Meinertz, P. Schnohr, and B. Nordestgaard, Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease, New England Journal of Medicine, vol.338, issue.22, pp.1577-1584, 1998.
DOI : 10.1056/NEJM199805283382203

M. Luke, J. Kane, D. Liu, C. Rowland, D. Shiffman et al., A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.27, issue.9, pp.2030-2036, 2007.
DOI : 10.1161/ATVBAHA.107.141291

D. Holmes, B. Schick, K. Humphries, and J. Frohlich, Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia, Clinical Chemistry, vol.51, issue.11, pp.2067-2073, 2005.
DOI : 10.1373/clinchem.2005.055228

D. Rader, W. Cain, K. Ikewaki, G. Talley, L. Zech et al., The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate., Journal of Clinical Investigation, vol.93, issue.6, pp.2758-2763, 1994.
DOI : 10.1172/JCI117292

M. Koschinsky and S. Marcovina, Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity, Current Opinion in Lipidology, vol.15, issue.2, pp.167-174, 2004.
DOI : 10.1097/00041433-200404000-00009

S. Marcovina, M. Koschinsky, J. Albers, and S. Skarlatos, Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions, Clinical Chemistry, vol.49, issue.11, pp.1785-1796, 2003.
DOI : 10.1373/clinchem.2003.023689

M. Koschinsky and S. Marcovina, Lipoprotein(a) In: Ballantyne C, ed. Clinical Lipidology: A Companion to Braunwauld's Heart Disease, pp.130-143, 2009.

L. Nielsen, Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux, Atherosclerosis, vol.143, issue.2, pp.229-243, 1999.
DOI : 10.1016/S0021-9150(99)00064-7

U. Lundstam, E. Hurt-camejo, G. Olsson, P. Sartipy, G. Camejo et al., Proteoglycans Contribution to Association of Lp(a) and LDL With Smooth Muscle Cell Extracellular Matrix, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.19, issue.5, pp.1162-1167, 1999.
DOI : 10.1161/01.ATV.19.5.1162

K. Bdeir, W. Cane, G. Canziani, I. Chaiken, J. Weisel et al., Defensin promotes the binding of lipoprotein(a) to vascular matrix, Blood, vol.94, pp.2007-2019, 1999.

N. Boonmark, X. Lou, Z. Yang, K. Schwartz, J. Zhang et al., Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice., Journal of Clinical Investigation, vol.100, issue.3, pp.558-564, 1997.
DOI : 10.1172/JCI119565

S. Sotiriou, V. Orlova, N. Al-fakhri, E. Ihanus, M. Economopoulou et al., Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin, The FASEB Journal, vol.20, pp.559-561, 2006.
DOI : 10.1096/fj.05-4857fje

S. Tsimikas, E. Brilakis, E. Miller, J. Mcconnell, R. Lennon et al., Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease, New England Journal of Medicine, vol.353, issue.1, pp.46-57, 2005.
DOI : 10.1056/NEJMoa043175

S. Tsimikas, L. Tsironis, and A. Tselepis, New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis and Cardiovascular Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.27, issue.10, pp.2094-2099, 2007.
DOI : 10.1161/01.ATV.0000280571.28102.d4

D. Rouy, P. Grailhe, F. Nigon, J. Chapman, and E. Angles-cano, Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue- type plasminogen activator. In vitro studies in a plasma milieu, vitro studies in a plasma milieu, pp.629-638, 1991.
DOI : 10.1161/01.ATV.11.3.629

N. Feric, M. Boffa, S. Johnston, and M. Koschinsky, Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation, Journal of Thrombosis and Haemostasis, vol.276, issue.12, pp.2113-2120, 2008.
DOI : 10.1111/j.1538-7836.2008.03183.x

S. Pan, L. Kleppe, T. Witt, C. Mueske, and R. Simari, The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis, Thrombosis and Haemostasis, vol.92, pp.495-502, 2004.
DOI : 10.1160/TH04-01-0006

L. Hervio, M. Chapman, J. Thillet, S. Loyau, and E. Angles-cano, Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?, Blood, vol.82, pp.392-397, 1993.

S. Erqou, A. Thompson, A. Di, D. Saleheen, S. Kaptoge et al., Apolipoprotein (a) Isoforms and the Risk of Vascular Disease: A Systematic Review of 40 Studies Involving 58,000 Participants, Journal of Vascular Surgery, vol.54, issue.1, pp.2160-2167, 2010.
DOI : 10.1016/j.jvs.2011.05.035

F. Kronenberg, M. Kronenberg, S. Kiechl, E. Trenkwalder, P. Santer et al., Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis : Prospective Results From the Bruneck Study, Circulation, vol.100, issue.11, pp.1154-1160, 1999.
DOI : 10.1161/01.CIR.100.11.1154

A. Von-eckardstein, H. Schulte, P. Cullen, and G. Assmann, Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk, Journal of the American College of Cardiology, vol.37, issue.2, pp.434-439, 2001.
DOI : 10.1016/S0735-1097(00)01126-8

I. Graham, D. Atar, K. Borch-johnsen, G. Boysen, G. Burell et al., European guidelines on cardiovascular disease prevention in clinical practice: Executive summary, Atherosclerosis, vol.194, issue.1, pp.2375-2414, 2007.
DOI : 10.1016/j.atherosclerosis.2007.08.024

S. Grundy, J. Cleeman, C. Merz, H. Brewer, . Jr et al., Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.8, pp.149-161, 2004.
DOI : 10.1161/01.ATV.0000133317.49796.0E

B. Nordestgaard, Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere, Current Opinion in Lipidology, vol.20, issue.5, pp.393-401, 2009.
DOI : 10.1097/MOL.0b013e3283307bfe

E. Bruckert, J. Labreuche, and P. Amarenco, Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis, Atherosclerosis, vol.210, issue.2, pp.353-361, 2010.
DOI : 10.1016/j.atherosclerosis.2009.12.023

L. Carlson and G. Rosenhamer, Reduction in mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid, Acta Med Scand, vol.233, pp.405-418, 1988.

P. Canner, K. Berge, N. Wenger, J. Stamler, L. Friedman et al., Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin, Journal of the American College of Cardiology, vol.8, issue.6, pp.1245-1255, 1986.
DOI : 10.1016/S0735-1097(86)80293-5

L. Cashin-hemphill, W. Mack, J. Pogoda, M. Sanmarco, S. Azen et al., Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up, JAMA: The Journal of the American Medical Association, vol.264, issue.23, pp.3013-3017, 1990.
DOI : 10.1001/jama.264.23.3013

G. Brown, J. Albers, L. Fisher, S. Schaefer, J. Lin et al., Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B, New England Journal of Medicine, vol.323, issue.19, pp.1289-1298, 1990.
DOI : 10.1056/NEJM199011083231901

A. Taylor, T. Villines, E. Stanek, P. Devine, L. Griffen et al., Extended-Release Niacin or Ezetimibe and Carotid Intima???Media Thickness, New England Journal of Medicine, vol.361, issue.22, pp.2113-2122, 2009.
DOI : 10.1056/NEJMoa0907569

M. Chapman, J. Redfern, M. Mcgovern, and P. Giral, Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk, Pharmacology & Therapeutics, vol.126, issue.3, pp.314-345, 2010.
DOI : 10.1016/j.pharmthera.2010.01.008

K. Tziomalos, V. Athyros, A. Wierzbicki, and D. Mikhailidis, Lipoprotein a: where are we now?, Current Opinion in Cardiology, vol.24, issue.4, pp.351-357, 2009.
DOI : 10.1097/HCO.0b013e32832ac21a

S. Gonbert, S. Malinsky, A. Sposito, H. Laouenan, C. Doucet et al., Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk, Atherosclerosis, vol.164, issue.2, pp.305-311, 2002.
DOI : 10.1016/S0021-9150(02)00072-2

D. Suk, N. Rifai, J. Buring, and P. Ridker, Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events, J Am Coll Cardiol, vol.52, pp.124-131, 2008.

V. Maher, B. Brown, S. Marcovina, L. Hillger, X. Zhao et al., Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a), JAMA: The Journal of the American Medical Association, vol.274, issue.22, pp.1771-1774, 1995.
DOI : 10.1001/jama.1995.03530220037029

E. Merki, M. Graham, A. Mullick, E. Miller, R. Crooke et al., Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice, Circulation, vol.118, issue.7, pp.743-753, 2008.
DOI : 10.1161/CIRCULATIONAHA.108.786822

P. Ladenson, J. Kristensen, E. Ridgway, A. Olsson, B. Carlsson et al., Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia, New England Journal of Medicine, vol.362, issue.10, pp.906-916, 2010.
DOI : 10.1056/NEJMoa0905633

G. Thompson, Recommendations for the use of LDL apheresis, Atherosclerosis, vol.198, issue.2, pp.247-255, 2008.
DOI : 10.1016/j.atherosclerosis.2008.02.009